Human TL1A (TNFSF15) Antibody - Tulisokibart Biosimilar

Anti-human TL1A (TNFSF15) - Tulisokibart biosimilar - CAS #2648504-55-4

Binding of Anti-hTL1A-hIgG1

Anti-hTL1A-hIgG1 is a biosimilar antibody of Tulisokibart, a therapeutic antibody that targets the tumor necrosis factor-like cytokine 1A (TL1A). This monoclonal antibody (mAb) blocks the interaction of TL1A with its receptor. Tulisokibart is being investigated for the treatment of IBD (Crohn’s disease and ulcerative colitis).

 More details

Anti-hTL1A-hIgG1 comprises the variable region of Tulisokibart and the IgG1 constant region of Tulisokibart with high effector functions. 

This antibody can be used together with HEK-Blue™ TL1A cells for screening and neutralization assays to block recombinant human TL1A-induced signaling  (see figure).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect assay

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ TL1A cell response using Tulisokibart biosimilar. Increasing concentrations of Anti-hTL1A-hIgG1 (0.01 ng/ml - 1 µg/ml) were incubated with recombinant human TL1A (3 ng/ml) for 1 h before the addition of HEK-Blue™ TL1A cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (mean ± SEM).

Specifications

Application: Neutralization assay, ELISA

Isotype:  Human IgG1, kappa

Recommended isotype control: Human IgG1

Target: Human TL1A (TNFSF15)

Species reactivity: Human

Clone: Tulisokibart, MK-7240, PRA023

Cas number: 2648504-55-4

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: ~144 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hTL1A-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in three quantities:

• htl1a-mab1: 100 µg
• htl1a-mab1-03: 3 x 100 µg
   

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

TL1A background

Tumor necrosis factor (TNF)-like 1A (TL1A), also called TNFSF15, is a cytokine that belongs to the TNF superfamily. TL1A is produced by endothelial cells, activated dendritic cells, and macrophages. It is synthesized as a membrane-bound trimeric molecule. Alternative splicing or cleavage by the tumor necrosis factor-alpha converting enzyme results in soluble TL1A [1]. Both forms bind the homotrimeric transmembrane death receptor 3 (DR3), triggering TRADD/TRAF2/RIP signaling, and ultimately leading to NF-κB and MAPKs activation. Subsequent gene expression in target cells drives the production of pro-inflammatory cytokines and differentiation of T helper subsets [1].
 

Relevance for therapeutics development

TL1A is normally responsible for mediating protective immune responses. However, it can also play a role in chronic inflammatory disorders and have harmful impacts. Abnormal TL1A expression or TL1A overactivity promotes excessive inflammation and immune cell infiltration, contributing to tissue damage and further inflammation amplification [1]. Pharmaceutical companies have developed potent monoclonal antibodies to block TL1A signaling and stop the downstream inflammatory cascade and tissue damage.
 

Tulisokibart background

Tulisokibart (MK-7240 or PRA023 from Merck) is a fully human anti-hTL1A-hIgG1 mAb designed to target the human tumor necrosis factor-like cytokine 1A (TL1A). This antibody specifically interacts with TL1A, thus preventing its binding to the TL1A receptor [1]. This monoclonal antibody (mAb) is being investigated for the treatment of IBD (Crohn’s disease and ulcerative colitis) [2].

References:

1. Xu, W.-D., R. Li, and A.-F. Huang, 2022. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review. Frontiers in Immunology, 13(891328).
2. Sands, B.E., et al., 2024. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med, 391(12): p. 1119-1129.